Atocha Romero, PharmD, PhD, Hospital Universitario Puerta de Hierro, discusses the rationale and trial design of the The Phase II NADIM II trial (NCT03838159), which was designed to explore neoadjuvant nivolumab plus chemotherapy versus chemotherapy alone in patients with locally advanced and potentially resectable non-small cell lung cancer (NSCLC). The aim was to validate the results found in the Phase II NADIM trial (NCT03081689) and the Phase III CheckMate 816 trial (NCT02998528). The primary endpoint was pathological complete response (pCR). Data on progression-free survival (PFS) and overall-survival (OS) was presented at WCLC 2022. Madrid, Spain. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
The rationale and trial design of the NADIM II trial
Теги
Speaker: Atocha RomeroInstitution: Hospital Universitario Puerta de HierroEvent: WCLC 2022Format: InterviewSubject: Lung CancerSubject: Non-Small Cell Lung CancerField: Trial UpdatesTrial: NADIMNCT03838159Field: TreatmentMedicines: PaclitaxelMedicines: CarboplatinMedicines: AntibodiesMedicines: NivolumabField: Immuno-OncologyField: Molecular ProfilingTrial: CheckMate 816NCT03081689NCT02998528pCROSPFS
